{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T14:34:44Z","timestamp":1762785284794,"version":"build-2065373602"},"reference-count":213,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Muscles"],"abstract":"<jats:p>Duchenne muscular dystrophy (DMD), which results from mutations that disrupt the expression of dystrophin proteins, is characterized by progressive muscle fiber wasting and the development of skeletal muscle fibrosis. The severe pathology leads to loss of ambulation, respiratory insufficiency, cardiomyopathy, and early death in patients. Dystrophin-focused therapies based on adeno-associated viral (AAV) vector-mediated gene addition, antisense oligonucleotide-induced repair of the transcript reading frame, and chemically driven stop codon readthrough have been conditionally approved for use in subsets of patients. From trials, it is apparent that these therapies act to stabilize the disease phenotype rather than improve it significantly, meaning that early treatment results in better outcomes. AAV-mediated delivery of a form of utrophin, a structural and functional homolog of dystrophin, GALGT2, a sarcolemmal stabilizer, and Klotho, the anti-aging hormone that is silenced in a mouse model of DMD as a result of the disease pathology, have been explored in preclinical compensatory gene addition studies. Recombinant follistatin protein has been used to target the fibrosis seen. An all-in-one type of therapy is likely to provide a synergistic effect such that efficacy of the dystrophin restoration strategy would be improved. For this, CRISPRa could hold potential through the targeting of multiple relevant genes simultaneously. The suitability of targeting these genes will be discussed, as will the stages of the development of CRISPRa for DMD. A perspective on the future prospects of CRISPRa in relation to likely issues that would need addressing and how they may be overcame will be given.<\/jats:p>","DOI":"10.3390\/muscles4040052","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T13:51:08Z","timestamp":1762782668000},"page":"52","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dystrophin Restorative and Compensatory Gene Addition Therapies for Duchenne Muscular Dystrophy: Could CRISPRa Provide a Realistic Alternative?"],"prefix":"10.3390","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0089-3983","authenticated-orcid":false,"given":"Zakaria","family":"Rostamitehrani","sequence":"first","affiliation":[{"name":"National Horizons Centre, School of Health and Life Sciences, Teesside University, Darlington DL1 1HG, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rida","family":"Javed","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences, School of Life Sciences and the Environment, Royal Holloway University of London, Egham TW20 0EX, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Popplewell","sequence":"additional","affiliation":[{"name":"National Horizons Centre, School of Health and Life Sciences, Teesside University, Darlington DL1 1HG, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/ptj\/85.12.1372","article-title":"The muscular dystrophies: From genes to therapies","volume":"85","author":"Lovering","year":"2005","journal-title":"Phys. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"488","DOI":"10.3325\/cmj.2019.60.488","article-title":"The prevalence of muscular dystrophy and spinal muscular atrophy in Croatia: Data from national and non-governmental organization registries","volume":"60","author":"Mihel","year":"2019","journal-title":"Croat. Med. J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1503\/cmaj.151384","article-title":"Myotonic dystrophy type 1","volume":"188","author":"Nguyen","year":"2016","journal-title":"Can. Med. Assoc. J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13023-020-01430-8","article-title":"Global epidemiology of Duchenne muscular dystrophy: An updated systematic review and meta-analysis","volume":"15","author":"Crisafulli","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1159\/000369343","article-title":"Prevalence of Muscular Dystrophies: A Systematic Literature Review","volume":"43","author":"Theadom","year":"2014","journal-title":"Neuroepidemiology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1212\/WNL.0000000000000797","article-title":"Population-based incidence and prevalence of facioscapulohumeral dystrophy","volume":"83","author":"Deenen","year":"2014","journal-title":"Neurology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/cge.14533","article-title":"Best practice guidelines on genetic diagnostics of facioscapulohumeral muscular dystrophy: Update of the 2012 guidelines","volume":"106","author":"Giardina","year":"2024","journal-title":"Clin. Genet."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/sj.embor.7400221","article-title":"Duchenne muscular dystrophy and dystrophin: Pathogenesis and opportunities for treatment","volume":"5","author":"Nowak","year":"2004","journal-title":"EMBO Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/j.2040-4603.2015.tb00638.x","article-title":"The Dystrophin Complex: Structure, Function, and Implications for Therapy","volume":"5","author":"Gao","year":"2015","journal-title":"Compr. Physiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1073\/pnas.90.8.3710","article-title":"Dystrophin protects the sarcolemma from stresses developed during muscle contraction","volume":"90","author":"Petrof","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Mareedu, S., Million, E.D., Duan, D., and Babu, G.J. (2021). Abnormal Calcium Handling in Duchenne Muscular Dystrophy: Mechanisms and Potential Therapies. Front. Physiol., 12.","DOI":"10.3389\/fphys.2021.647010"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.scr.2014.10.007","article-title":"Satellite cells from dystrophic muscle retain regenerative capacity","volume":"14","author":"Boldrin","year":"2015","journal-title":"Stem Cell Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1152\/japplphysiol.00248.2021","article-title":"Diaphragm muscle fibrosis involves changes in collagen organization with mechanical implications in Duchenne muscular dystrophy","volume":"132","author":"Sahani","year":"2022","journal-title":"J. Appl. Physiol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Kharraz, Y., Guerra, J., Pessina, P., Serrano, A.L., and Mu\u00f1oz-C\u00e1noves, P. (2014). Understanding the process of fibrosis in Duchenne muscular dystrophy. BioMed Res. Int., 2014.","DOI":"10.1155\/2014\/965631"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/21678707.2018.1438261","article-title":"The potential of utrophin modulators for the treatment of Duchenne muscular dystrophy","volume":"6","author":"Guiraud","year":"2018","journal-title":"Expert Opin. Orphan Drugs"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41536-018-0045-4","article-title":"Humanizing the mdx mouse model of DMD: The long and the short of it","volume":"3","author":"Yucel","year":"2018","journal-title":"npj Regen. Med."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Yao, S., Chen, Z., Yu, Y., Zhang, N., Jiang, H., Zhang, G., Zhang, Z., and Zhang, B. (2021). Current Pharmacological Strategies for Duchenne Muscular Dystrophy. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.689533"},{"key":"ref_18","first-page":"CD003725","article-title":"Corticosteroids for the treatment of Duchenne muscular dystrophy","volume":"5","author":"Matthews","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_19","first-page":"jrm00250","article-title":"Exercise Training in Duchenne Muscular Dystrophy: A Systematic Review and Meta-Analysis","volume":"54","author":"Hammer","year":"2022","journal-title":"J. Rehabil. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/bja\/60.2.228","article-title":"Muscle Relaxation in Patients with Duchenne\u2019s Muscular Dystrophy: Use of Vecuronium in Two Patients","volume":"60","author":"Buzello","year":"1988","journal-title":"Br. J. Anaesth."},{"key":"ref_21","first-page":"21","article-title":"Surgical treatment of Duchenne muscular dystrophy patients in Germany: The present situation","volume":"31","author":"Forst","year":"2012","journal-title":"Acta Myol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2217\/cer-2019-0086","article-title":"Ataluren use in patients with nonsense mutation Duchenne muscular dystrophy: Patient demographics and characteristics from the STRIDE Registry","volume":"8","author":"Muntoni","year":"2019","journal-title":"J. Comp. Eff. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e2020599118","DOI":"10.1073\/pnas.2020599118","article-title":"Ataluren and aminoglycosides stimulate read-through of nonsense codons by orthogonal mechanisms","volume":"118","author":"Ng","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Finkel, R.S., Flanigan, K.M., Wong, B., B\u00f6nnemann, C., Sampson, J., Sweeney, H.L., Reha, A., Northcutt, V.J., Elfring, G., and Barth, J. (2013). Phase 2a Study of Ataluren-Mediated Dystrophin Production in Patients with Nonsense Mutation Duchenne Muscular Dystrophy. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0081302"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10974-019-09535-9","article-title":"What is the level of dystrophin expression required for effective therapy of Duchenne muscular dystrophy?","volume":"40","author":"Wells","year":"2019","journal-title":"J. Muscle Res. Cell Motil."},{"key":"ref_26","first-page":"43","article-title":"Read-through approach for stop mutations in Duchenne muscular dystrophy. An update","volume":"40","author":"Politano","year":"2021","journal-title":"Acta Myol."},{"key":"ref_27","unstructured":"European Medicines Agency (2025, August 01). Translarna: EMA Re-Confirms Non-Renewal of Authorisation of Duchenne Muscular Dystrophy Medicine. Available online: https:\/\/www.ema.europa.eu\/en\/news\/translarna-ema-re-confirms-non-renewal-authorisation-duchenne-muscular-dystrophy-medicine."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/jhg.2017.57","article-title":"Moving towards successful exon-skipping therapy for Duchenne muscular dystrophy","volume":"62","author":"Nakamura","year":"2017","journal-title":"J. Hum. Genet."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1261\/rna.653607","article-title":"Antisense-mediated exon skipping: A versatile tool with therapeutic and research applications","volume":"13","year":"2007","journal-title":"RNA"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3233\/JND-221648","article-title":"The Dilemma of Choice for Duchenne Patients Eligible for Exon 51 Skipping the European Experience","volume":"10","author":"Kirschner","year":"2023","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2174\/1389202920666191107142754","article-title":"Repurposing Pathogenic Variants of DMD Gene and its Isoforms for DMD Exon Skipping Intervention","volume":"20","author":"Tyagi","year":"2019","journal-title":"Curr. Genom."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40478-020-01106-1","article-title":"The administration of antisense oligonucleotide golodirsen reduces pathological regeneration in patients with Duchenne muscular dystrophy","volume":"9","author":"Scaglioni","year":"2021","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Eser, G., and Topalo\u011flu, H. (2022). Current Outline of Exon Skipping Trials in Duchenne Muscular Dystrophy. Genes, 13.","DOI":"10.3390\/genes13071241"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"230fs214","DOI":"10.1126\/scitranslmed.3008873","article-title":"Exon-skipping therapy: A roadblock, detour, or bump in the road?","volume":"6","author":"Hoffman","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3233\/JND-210665","article-title":"A Combined Prospective and Retrospective Comparison of Long-Term Functional Outcomes Suggests Delayed Loss of Ambulation and Pulmonary Decline with Long-Term Eteplirsen Treatment","volume":"9","author":"Mitelman","year":"2022","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3233\/JND-200548","article-title":"Comparison of Long-term Ambulatory Function in Patients with Duchenne Muscular Dystrophy Treated with Eteplirsen and Matched Natural History Controls","volume":"8","author":"Mendell","year":"2021","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","article-title":"Adeno-Associated Virus (AAV) as a Vector for Gene Therapy","volume":"31","author":"Naso","year":"2017","journal-title":"BioDrugs"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/d41573-023-00103-y","article-title":"FDA approves first gene therapy for Duchenne muscular dystrophy, despite internal objections","volume":"22","author":"Mullard","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1016\/j.ymthe.2018.07.011","article-title":"Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy","volume":"26","author":"Duan","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Cernisova, V., Lu-Nguyen, N., Trundle, J., Herath, S., Malerba, A., and Popplewell, L. (2023). Microdystrophin Gene Addition Significantly Improves Muscle Functionality and Diaphragm Muscle Histopathology in a Fibrotic Mouse Model of Duchenne Muscular Dystrophy. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24098174"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Wilton-Clark, H., and Yokota, T. (2022). Antisense and Gene Therapy Options for Duchenne Muscular Dystrophy Arising from Mutations in the N-Terminal Hotspot. Genes, 13.","DOI":"10.3390\/genes13020257"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Hart, C.C., Lee, Y.i., Xie, J., Gao, G., Lin, B.L., Hammers, D.W., and Sweeney, H.L. (2024). Potential limitations of microdystrophin gene therapy for Duchenne muscular dystrophy. JCI Insight, 9.","DOI":"10.1172\/jci.insight.165869"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s43440-020-00134-x","article-title":"Muscle and cardiac therapeutic strategies for Duchenne muscular dystrophy: Past, present, and future","volume":"72","author":"Dulak","year":"2020","journal-title":"Pharmacol. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"131617","DOI":"10.1016\/j.ijcard.2023.131617","article-title":"Gene therapy vector-related myocarditis","volume":"398","author":"Silver","year":"2024","journal-title":"Int. J. Cardiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e146511","DOI":"10.1172\/jci.insight.146511","article-title":"Micro-dystrophin gene therapy prevents heart failure in an improved Duchenne muscular dystrophy cardiomyopathy mouse model","volume":"6","author":"Howard","year":"2021","journal-title":"JCI Insight"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.jacbts.2024.12.015","article-title":"Long-Term Dystrophin Replacement Therapy in Duchenne Muscular Dystrophy Causes Cardiac Inflammation","volume":"10","author":"Forand","year":"2025","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.pediatrneurol.2024.01.003","article-title":"Practical Considerations for Delandistrogene Moxeparvovec Gene Therapy in Patients with Duchenne Muscular Dystrophy","volume":"153","author":"Mendell","year":"2024","journal-title":"Pediatr. Neurol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s40265-023-01929-x","article-title":"Delandistrogene Moxeparvovec: First Approval","volume":"83","author":"Hoy","year":"2023","journal-title":"Drugs"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1212\/WNL.0000000000203455","article-title":"EMBARK, a Phase 3 Trial Evaluating Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Duchenne Muscular Dystrophy (DMD): Study Design and Baseline Characteristics (P5-8.012)","volume":"100","author":"Muntoni","year":"2023","journal-title":"Neurology"},{"key":"ref_50","unstructured":"Sarepta Therapeutics, I. (2025, July 21). Sarepta Therapeutics Announces Voluntary Pause of ELEVIDYS Shipments in the U.S. Available online: https:\/\/investorrelations.sarepta.com\/news-releases\/news-release-details\/sarepta-therapeutics-announces-voluntary-pause-elevidys."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/j.nmd.2022.07.246","article-title":"P.130 RGX-202: An investigational AAV8 gene therapy coding for a novel microdystrophin as a treatment for Duchenne muscular dystrophy","volume":"32","author":"Dastgir","year":"2022","journal-title":"Neuromuscul. Disord."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/s41573-023-00775-6","article-title":"Therapeutic approaches for Duchenne muscular dystrophy","volume":"22","author":"Roberts","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"104441.104281","DOI":"10.1016\/j.nmd.2024.07.290","article-title":"410P GNT0004, Genethon\u2019s AAV8 vector-delivered microdystrophin gene therapy of Duchenne muscular dystrophy, first data of the phase I\/II part of the GNT-016-MDYF all-in-one clinical trial in ambulant boys","volume":"43","author":"Laugel","year":"2024","journal-title":"Neuromuscul. Disord."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.omtm.2022.08.009","article-title":"A first-in-human phase I\/IIa gene transfer clinical trial for Duchenne muscular dystrophy using rAAVrh74.MCK.GALGT2","volume":"27","author":"Flanigan","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/mt.2014.200","article-title":"A Phase 1\/2a Follistatin Gene Therapy Trial for Becker Muscular Dystrophy","volume":"23","author":"Mendell","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"R102","DOI":"10.1093\/hmg\/ddz128","article-title":"AAV-based gene therapies for the muscular dystrophies","volume":"28","author":"Crudele","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Rajaganapathy, S., McCourt, J.L., Ghosal, S., Lindsay, A., McCourt, P.M., Lowe, D.A., Ervasti, J.M., and Salapaka, M.V. (2019). Distinct mechanical properties in homologous spectrin-like repeats of utrophin. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-41569-4"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/nan.12735","article-title":"Utrophin modulator drugs as potential therapies for Duchenne and Becker muscular dystrophies","volume":"47","year":"2021","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.coph.2017.04.002","article-title":"Pharmacological advances for treatment in Duchenne muscular dystrophy","volume":"34","author":"Guiraud","year":"2017","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1113\/EP085308","article-title":"Advances in genetic therapeutic strategies for Duchenne muscular dystrophy","volume":"100","author":"Guiraud","year":"2015","journal-title":"Exp. Physiol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/BF02388063","article-title":"Dystrophin-related protein, utrophin, in normal and dystrophic human fetal skeletal muscle","volume":"25","author":"Clerk","year":"1993","journal-title":"Histochem. J."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.medj.2023.03.005","article-title":"Utrophin correlates with disease severity in Duchenne muscular dystrophy","volume":"4","author":"Guiraud","year":"2023","journal-title":"Med"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.medj.2023.02.005","article-title":"Unusually severe muscular dystrophy upon in-frame deletion of the dystrophin rod domain and lack of compensation by membrane-localized utrophin","volume":"4","author":"Gorokhova","year":"2023","journal-title":"Med"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Chatzopoulou, M., Conole, D., Emer, E., Rowley, J.A., Willis, N.J., Squire, S.E., Gill, B., Brough, S., Wilson, F.X., and Wynne, G.M. (2022). Structure-activity relationships of 2-pyrimidinecarbohydrazides as utrophin modulators for the potential treatment of Duchenne muscular dystrophy. Bioorganic Med. Chem., 69.","DOI":"10.1016\/j.bmc.2022.116812"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Tinsley, J.M., Fairclough, R.J., Storer, R., Wilkes, F.J., Potter, A.C., Squire, S.E., Powell, D.S., Cozzoli, A., Capogrosso, R.F., and Lambert, A. (2011). Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0019189"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Markati, T., De Waele, L., Schara-Schmidt, U., and Servais, L. (2021). Lessons Learned from Discontinued Clinical Developments in Duchenne Muscular Dystrophy. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.735912"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"113431","DOI":"10.1016\/j.ejmech.2021.113431","article-title":"Discovery and mechanism of action studies of 4,6-diphenylpyrimidine-2-carbohydrazides as utrophin modulators for the treatment of Duchenne muscular dystrophy","volume":"220","author":"Vuorinen","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"130819","DOI":"10.1016\/j.tet.2019.130819","article-title":"Synthesis of SMT022357 enantiomers and in vivo evaluation in a Duchenne muscular dystrophy mouse model","volume":"76","author":"Babbs","year":"2020","journal-title":"Tetrahedron"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Song, M.H., Yoo, J., Oh, J.G., Kook, H., Park, W.J., and Jeong, D. (2022). Matricellular Protein CCN5 Gene Transfer Ameliorates Cardiac and Skeletal Dysfunction in mdx\/utrn (\u00b1) Haploinsufficient Mice by Reducing Fibrosis and Upregulating Utrophin Expression. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.763544"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"9260","DOI":"10.1021\/acs.jmedchem.4c00398","article-title":"Discovery of Quinazoline and Quinoline-Based Small Molecules as Utrophin Upregulators via AhR Antagonism for the Treatment of Duchenne Muscular Dystrophy","volume":"67","author":"Ghosh","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"24707","DOI":"10.1021\/acsomega.4c01225","article-title":"3D-QSAR Modeling on 2-Pyrimidine Carbohydrazides as Utrophin Modulators for the Treatment of Duchenne Muscular Dystrophy by Combining CoMFA, CoMSIA, and Molecular Docking Studies","volume":"9","author":"Pourbasheer","year":"2024","journal-title":"ACS Omega"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"7880","DOI":"10.1021\/acs.jmedchem.0c00807","article-title":"2-Arylbenzo[d]oxazole Phosphinate Esters as Second-Generation Modulators of Utrophin for the Treatment of Duchenne Muscular Dystrophy","volume":"63","author":"Babbs","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"34720","DOI":"10.1074\/jbc.M804518200","article-title":"Targeting Artificial Transcription Factors to the Utrophin A Promoter: Effects on Dystrophic Pathology and Muscle Function *","volume":"283","author":"Lu","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1002\/jcp.24567","article-title":"Novel Adeno-Associated Viral Vector Delivering the Utrophin Gene Regulator Jazz Counteracts Dystrophic Pathology in mdx Mice","volume":"229","author":"Strimpakos","year":"2014","journal-title":"J. Cell. Physiol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.bbadis.2018.01.030","article-title":"Utrophin up-regulation by artificial transcription factors induces muscle rescue and impacts the neuromuscular junction in mdx mice","volume":"1864","author":"Pisani","year":"2018","journal-title":"Biochim. Biophys. Acta BBA-Mol. Basis Dis."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.omtn.2020.08.031","article-title":"Genome Editing-Mediated Utrophin Upregulation in Duchenne Muscular Dystrophy Stem Cells","volume":"22","author":"Sengupta","year":"2020","journal-title":"Mol. Ther.-Nucleic Acids"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.omtn.2018.05.011","article-title":"MicroRNA-206 Downregulation Improves Therapeutic Gene Expression and Motor Function in mdx Mice","volume":"12","author":"Bulaklak","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Sengupta, K., Loro, E., and Khurana, T.S. (2020). PMO-based let-7c site blocking oligonucleotide (SBO) mediated utrophin upregulation in mdx mice, a therapeutic approach for Duchenne muscular dystrophy (DMD). Sci. Rep., 10.","DOI":"10.1038\/s41598-020-76338-1"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1016\/j.ymthe.2019.10.011","article-title":"Micro-utrophin Therapy for Duchenne Muscular Dystrophy","volume":"27","author":"Duan","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Starikova, A.V., Skopenkova, V.V., Polikarpova, A.V., Reshetov, D.A., Vassilieva, S.G., Velyaev, O.A., Shmidt, A.A., Savchenko, I.M., Soldatov, V.O., and Egorova, T.V. (2022). Therapeutic potential of highly functional codon-optimized microutrophin for muscle-specific expression. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-04892-x"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.omtm.2018.10.005","article-title":"Micro-utrophin Improves Cardiac and Skeletal Muscle Function of Severely Affected D2\/mdx Mice","volume":"11","author":"Kennedy","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1038\/s41591-019-0594-0","article-title":"Non-immunogenic utrophin gene therapy for the treatment of muscular dystrophy animal models","volume":"25","author":"Song","year":"2019","journal-title":"Nat. Med."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Banks, G.B., Chamberlain, J.S., and Odom, G.L. (2020). Microutrophin expression in dystrophic mice displays myofiber type differences in therapeutic effects. PLoS Genet., 16.","DOI":"10.1371\/journal.pgen.1009179"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1038\/mt.2008.149","article-title":"Microutrophin Delivery Through rAAV6 Increases Lifespan and Improves Muscle Function in Dystrophic Dystrophin\/Utrophin-deficient Mice","volume":"16","author":"Odom","year":"2008","journal-title":"Mol. Ther."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"5447","DOI":"10.1007\/s00018-021-03862-2","article-title":"The multifaceted view of heart problem in Duchenne muscular dystrophy","volume":"78","author":"Polak","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"118954","DOI":"10.1016\/j.lfs.2020.118954","article-title":"The \u201cirisin system\u201d: From biological roles to pharmacological and nutraceutical perspectives","volume":"267","author":"Flori","year":"2021","journal-title":"Life Sci."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3233\/JND-150083","article-title":"Follistatin Gene Therapy Improves Ambulation in Becker Muscular Dystrophy","volume":"2","author":"Sahenk","year":"2015","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.ajpath.2011.04.008","article-title":"Follistatin Improves Skeletal Muscle Healing after Injury and Disease through an Interaction with Muscle Regeneration, Angiogenesis, and Fibrosis","volume":"179","author":"Zhu","year":"2011","journal-title":"Am. J. Pathol."},{"key":"ref_89","first-page":"342","article-title":"Leveraging Quantitative Systems Pharmacology Approach into Development of Human Recombinant Follistatin Fusion Protein for Duchenne Muscular Dystrophy","volume":"9","author":"Nguyen","year":"2020","journal-title":"CPT: Pharmacomet. Syst. Pharmacol."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Pearsall, R.S., Davies, M.V., Cannell, M., Li, J., Widrick, J., Mulivor, A.W., Wallner, S., Troy, M.E., Spaits, M., and Liharska, K. (2019). Follistatin-based ligand trap ACE-083 induces localized hypertrophy of skeletal muscle with functional improvement in models of neuromuscular disease. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-47818-w"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1124\/jpet.118.248195","article-title":"Protein Engineering on Human Recombinant Follistatin: Enhancing Pharmacokinetic Characteristics for Therapeutic Application","volume":"366","author":"Shen","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2021.04.001","article-title":"Principles of the activin receptor signaling pathway and its inhibition","volume":"60","author":"Lodberg","year":"2021","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/mt.2013.246","article-title":"Vascular Delivery of rAAVrh74.MCK.GALGT2 to the Gastrocnemius Muscle of the Rhesus Macaque Stimulates the Expression of Dystrophin and Laminin \u03b12 Surrogates","volume":"22","author":"Chicoine","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0169-328X(02)00551-X","article-title":"Definition of pre- and postsynaptic forms of the CT carbohydrate antigen at the neuromuscular junction: Ubiquitous expression of the CT antigens and the CT GalNAc transferase in mouse tissues","volume":"109","author":"Hoyte","year":"2002","journal-title":"Mol. Brain Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1073\/pnas.082613599","article-title":"Overexpression of the cytotoxic T cell GalNAc transferase in skeletal muscle inhibits muscular dystrophy in mdx mice","volume":"99","author":"Nguyen","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/0896-6273(91)90301-F","article-title":"Dystrophin-related protein is localized to neuromuscular junctions of adult skeletal muscle","volume":"7","author":"Ohlendieck","year":"1991","journal-title":"Neuron"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.mcn.2009.04.013","article-title":"The synaptic CT carbohydrate modulates binding and expression of extracellular matrix proteins in skeletal muscle: Partial dependence on utrophin","volume":"41","author":"Yoon","year":"2009","journal-title":"Mol. Cell. Neurosci."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.ymthe.2019.01.005","article-title":"rAAVrh74.MCK.GALGT2 Protects against Loss of Hemodynamic Function in the Aging mdx Mouse Heart","volume":"27","author":"Xu","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1016\/j.ajpath.2015.06.008","article-title":"Deletion of Galgt2 (B4Galnt2) Reduces Muscle Growth in Response to Acute Injury and Increases Muscle Inflammation and Pathology in Dystrophin-Deficient Mice","volume":"185","author":"Xu","year":"2015","journal-title":"Am. J. Pathol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"C476","DOI":"10.1152\/ajpcell.00456.2008","article-title":"Overexpression of Galgt2 in skeletal muscle prevents injury resulting from eccentric contractions in both mdx and wild-type mice","volume":"296","author":"Martin","year":"2009","journal-title":"Am. J. Physiol.-Cell Physiol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.nmd.2006.12.004","article-title":"Postnatal overexpression of the CT GalNAc transferase inhibits muscular dystrophy in mdx mice without altering muscle growth or neuromuscular development: Evidence for a utrophin-independent mechanism","volume":"17","author":"Xu","year":"2007","journal-title":"Neuromuscul. Disord."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Martin, P.T., Zygmunt, D.A., Ashbrook, A., Hamilton, S., Packer, D., Birch, S.M., Bettis, A.K., Balog-Alvarez, C.J., Guo, L.-J., and Nghiem, P.P. (2021). Short-term treatment of golden retriever muscular dystrophy (GRMD) dogs with rAAVrh74.MHCK7.GALGT2 induces muscle glycosylation and utrophin expression but has no significant effect on muscle strength. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0248721"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.omtm.2019.10.005","article-title":"rAAVrh74.MCK.GALGT2 Demonstrates Safety and Widespread Muscle Glycosylation after Intravenous Delivery in C57BL\/6J Mice","volume":"15","author":"Zygmunt","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"5660","DOI":"10.1021\/acsnano.1c10631","article-title":"Robust, Durable Gene Activation In Vivo via mRNA-Encoded Activators","volume":"16","author":"Beyersdorf","year":"2022","journal-title":"ACS Nano"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15280\/jlm.2015.5.1.1","article-title":"Biological Role of Anti-aging Protein Klotho","volume":"5","author":"Kim","year":"2015","journal-title":"J. Lifestyle Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3904\/kjim.2011.26.2.113","article-title":"Klotho and the aging process","volume":"26","year":"2011","journal-title":"Korean J. Intern. Med."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Mota, J., Lima, A.M.M., Gomes, J.I.S., Souza de Andrade, M., Brito, H.O., Silva, M.M.A.L., Faustino-Rocha, A.I., Oliveira, P.A., Lopes, F.F., and Gil da Costa, R.M. (2023). Klotho in Cancer: Potential Diagnostic and Prognostic Applications. Diagnostics, 13.","DOI":"10.3390\/diagnostics13213357"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Buchanan, S., Combet, E., Stenvinkel, P., and Shiels, P.G. (2020). Klotho, Aging, and the Failing Kidney. Front. Endocrinol., 11.","DOI":"10.3389\/fendo.2020.00560"},{"key":"ref_109","first-page":"2465","article-title":"Klotho gene silencing promotes pathology in the mdx mouse model of Duchenne muscular dystrophy","volume":"25","author":"Li","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"S271","DOI":"10.3233\/JND-210703","article-title":"Female Outperformance in Voluntary Running Persists in Dystrophin-Null and Klotho-Overexpressing Mice","volume":"8","author":"Phelps","year":"2021","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.ajpath.2024.12.017","article-title":"Klotho Is Cardioprotective in the mdx Mouse Model of Duchenne Muscular Dystrophy","volume":"195","author":"Javier","year":"2025","journal-title":"Am. J. Pathol."},{"key":"ref_112","unstructured":"Feldman, A. (Forbes, 2025). InnovationRx: Sarepta Blinks in Showdown with FDA, Forbes."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1016\/j.ymthe.2023.10.015","article-title":"Lethal immunotoxicity in high-dose systemic AAV therapy","volume":"31","author":"Duan","year":"2023","journal-title":"Mol. Ther."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1089\/hum.2023.057","article-title":"Progress in Bioengineering of Myotropic Adeno-Associated Viral Gene Therapy Vectors","volume":"34","author":"Liu","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"eabd3438","DOI":"10.1126\/scitranslmed.abd3438","article-title":"Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses","volume":"13","author":"Chan","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Muhuri, M., Zhan, W., Maeda, Y., Li, J., Lotun, A., Chen, J., Sylvia, K., Dasgupta, I., Arjomandnejad, M., and Nixon, T. (2021). Novel Combinatorial MicroRNA-Binding Sites in AAV Vectors Synergistically Diminish Antigen Presentation and Transgene Immunity for Efficient and Stable Transduction. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.674242"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1161\/CIRCULATIONAHA.122.063759","article-title":"Extracellular Vesicle\u2013Encapsulated Adeno-Associated Viruses for Therapeutic Gene Delivery to the Heart","volume":"148","author":"Li","year":"2023","journal-title":"Circulation"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Gy\u00f6rgy, B., and Maguire, C.A. (2018). Extracellular vesicles: Nature\u2019s nanoparticles for improving gene transfer with adeno-associated virus vectors. WIREs Nanomed. Nanobiotechnol., 10.","DOI":"10.1002\/wnan.1488"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"815","DOI":"10.3233\/JND-210662","article-title":"Electrostatic Coating of Viral Particles for Gene Delivery Applications in Muscular Dystrophies: Influence of Size on Stability and Antibody Protection","volume":"8","author":"Stampa","year":"2021","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Cordova, G., Negroni, E., Cabello-Verrugio, C., Mouly, V., and Trollet, C. (2018). Combined Therapies for Duchenne Muscular Dystrophy to Optimize Treatment Efficacy. Front. Genet., 9.","DOI":"10.3389\/fgene.2018.00114"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1093\/hmg\/ddab120","article-title":"Combined gene therapy via VEGF and mini-dystrophin synergistically improves pathologies in temporalis muscle of dystrophin\/utrophin double knockout mice","volume":"30","author":"Xin","year":"2021","journal-title":"Hum. Mol. Genet."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1016\/j.csbj.2020.08.031","article-title":"CRISPR-Cas systems: Overview, innovations and applications in human disease research and gene therapy","volume":"18","author":"Xu","year":"2020","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1021\/acschembio.7b00657","article-title":"CRISPRi and CRISPRa Screens in Mammalian Cells for Precision Biology and Medicine","volume":"13","author":"Kampmann","year":"2018","journal-title":"ACS Chem. Biol."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Carroll, M.S., and Giacca, M. (2023). CRISPR activation and interference as investigative tools in the cardiovascular system. Int. J. Biochem. Cell Biol., 155.","DOI":"10.1016\/j.biocel.2022.106348"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1101\/gr.275607.121","article-title":"Targeted regulation of transcription in primary cells using CRISPRa and CRISPRi","volume":"31","author":"Jensen","year":"2021","journal-title":"Genome Res."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Omachi, K., and Miner, J.H. (2022). Comparative analysis of dCas9-VP64 variants and multiplexed guide RNAs mediating CRISPR activation. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0270008"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/cr.2013.122","article-title":"Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system","volume":"23","author":"Cheng","year":"2013","journal-title":"Cell Res."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.cell.2014.09.029","article-title":"Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation","volume":"159","author":"Gilbert","year":"2014","journal-title":"Cell"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/nmeth.2598","article-title":"CRISPR RNA\u2013guided activation of endogenous human genes","volume":"10","author":"Maeder","year":"2013","journal-title":"Nat. Methods"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nmeth.2600","article-title":"RNA-guided gene activation by CRISPR-Cas9\u2013based transcription factors","volume":"10","author":"Kocak","year":"2013","journal-title":"Nat. Methods"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1002\/j.1460-2075.1992.tb05603.x","article-title":"Different activation domains stimulate transcription from remote (\u2018enhancer\u2019) and proximal (\u2018promoter\u2019) positions","volume":"11","author":"Seipel","year":"1992","journal-title":"Embo J."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nature14136","article-title":"Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex","volume":"517","author":"Konermann","year":"2015","journal-title":"Nature"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.tibtech.2024.02.007","article-title":"CRISPR activation screens: Navigating technologies and applications","volume":"42","author":"Clark","year":"2024","journal-title":"Trends Biotechnol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1021\/sb400081r","article-title":"Tunable and Multifunctional Eukaryotic Transcription Factors Based on CRISPR\/Cas","volume":"2","author":"Farzadfard","year":"2013","journal-title":"ACS Synth. Biol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.cell.2013.06.044","article-title":"CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes","volume":"154","author":"Gilbert","year":"2013","journal-title":"Cell"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1242\/dev.103341","article-title":"Cas9 effector-mediated regulation of transcription and differentiation in human pluripotent stem cells","volume":"141","author":"Kearns","year":"2014","journal-title":"Development"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.omtn.2016.11.004","article-title":"Increased Expression of Laminin Subunit Alpha 1 Chain by dCas9-VP160","volume":"6","author":"Perrin","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"e201900497","DOI":"10.26508\/lsa.201900497","article-title":"Sufficiency analysis of estrogen responsive enhancers using synthetic activators","volume":"2","author":"Carleton","year":"2019","journal-title":"Life Sci. Alliance"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.stemcr.2015.08.001","article-title":"Conditionally Stabilized dCas9 Activator for Controlling Gene Expression in Human Cell Reprogramming and Differentiation","volume":"5","author":"Balboa","year":"2015","journal-title":"Stem Cell Rep."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.cell.2014.09.039","article-title":"A Protein-Tagging System for Signal Amplification in Gene Expression and Fluorescence Imaging","volume":"159","author":"Tanenbaum","year":"2014","journal-title":"Cell"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1089\/crispr.2021.0099","article-title":"CRISPR-Mediated Synergistic Epigenetic and Transcriptional Control","volume":"5","author":"Dominguez","year":"2022","journal-title":"Cris. J."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41593-017-0060-6","article-title":"In vivo simultaneous transcriptional activation of multiple genes in the brain using CRISPR\u2013dCas9-activator transgenic mice","volume":"21","author":"Zhou","year":"2018","journal-title":"Nat. Neurosci."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/nar\/gkad1108","article-title":"A modular dCas9-based recruitment platform for combinatorial epigenome editing","volume":"52","author":"Swain","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1089\/crispr.2018.0009","article-title":"Three-Component Repurposed Technology for Enhanced Expression: Highly Accumulable Transcriptional Activators via Branched Tag Arrays","volume":"1","author":"Kunii","year":"2018","journal-title":"Cris. J."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/s41477-017-0046-0","article-title":"A potent Cas9-derived gene activator for plant and mammalian cells","volume":"3","author":"Li","year":"2017","journal-title":"Nat. Plants"},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Young, J.K., Gasior, S.L., Jones, S., Wang, L., Navarro, P., Vickroy, B., and Barrangou, R. (2019). The repurposing of type I-E CRISPR-Cascade for gene activation in plants. Commun. Biol., 2.","DOI":"10.1038\/s42003-019-0637-6"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nchembio.1753","article-title":"A light-inducible CRISPR-Cas9 system for control of endogenous gene activation","volume":"11","author":"Polstein","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s00018-022-04175-8","article-title":"Maybe you can turn me on: CRISPRa-based strategies for therapeutic applications","volume":"79","author":"Becirovic","year":"2022","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"B\u00f6hm, S., Riedmayr, L.M., Nguyen, O.N.P., Gie\u00dfl, A., Liebscher, T., Butz, E.S., Sch\u00f6n, C., Michalakis, S., Wahl-Schott, C., and Biel, M. (2017). Peripherin-2 and Rom-1 have opposing effects on rod outer segment targeting of retinitis pigmentosa-linked peripherin-2 mutants. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-02514-5"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.cell.2017.10.025","article-title":"In Vivo Target Gene Activation via CRISPR\/Cas9-Mediated Trans-epigenetic Modulation","volume":"171","author":"Liao","year":"2017","journal-title":"Cell"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/s41590-019-0500-4","article-title":"Multiplexed activation of endogenous genes by CRISPRa elicits potent antitumor immunity","volume":"20","author":"Wang","year":"2019","journal-title":"Nat. Immunol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1056\/NEJMoa2307798","article-title":"Death after High-Dose rAAV9 Gene Therapy in a Patient with Duchenne\u2019s Muscular Dystrophy","volume":"389","author":"Lek","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_153","unstructured":"U.S. Food and Drug Administration (2025). ZOLGENSMA (Onasemnogene Abeparvovec-xioi) Prescribing Information."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1056\/NEJMoa2009965","article-title":"Risdiplam in Type 1 Spinal Muscular Atrophy","volume":"384","author":"Baranello","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy","volume":"377","author":"Shell","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s12031-017-1011-0","article-title":"Activation of the Anti-Aging and Cognition-Enhancing Gene Klotho by CRISPR-dCas9 Transcriptional Effector Complex","volume":"64","author":"Chen","year":"2018","journal-title":"J. Mol. Neurosci."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1038\/s41467-025-57831-5","article-title":"Activation of endogenous full-length utrophin by MyoAAV-UA as a therapeutic approach for Duchenne muscular dystrophy","volume":"16","author":"Wu","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1038\/s41467-022-31798-z","article-title":"Inactivation of Sirt6 ameliorates muscular dystrophy in mdx mice by releasing suppression of utrophin expression","volume":"13","author":"Georgieva","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/gt.2010.157","article-title":"Liver-specific microRNA-122 target sequences incorporated in AAV vectors efficiently inhibits transgene expression in the liver","volume":"18","author":"Qiao","year":"2011","journal-title":"Gene Ther."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1080\/00207454.2024.2302551","article-title":"Identifying hub genes and dysregulated pathways in Duchenne muscular dystrophy","volume":"135","author":"Xin","year":"2025","journal-title":"Int. J. Neurosci."},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Wang, J., Fan, Q., Yu, T., and Zhang, Y. (2021). Identifying the hub genes for Duchenne muscular dystrophy and Becker muscular dystrophy by weighted correlation network analysis. BMC Genom. Data, 22.","DOI":"10.1186\/s12863-021-01014-w"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/s41419-023-06103-5","article-title":"Decoding the transcriptome of Duchenne muscular dystrophy to the single nuclei level reveals clinical-genetic correlations","volume":"14","author":"Natera","year":"2023","journal-title":"Cell Death Dis."},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"Sothers, H., Hu, X., Crossman, D.K., Si, Y., Alexander, M.S., McDonald, M.-L.N., King, P.H., and Lopez, M.A. (2024). Late-Stage Skeletal Muscle Transcriptome in Duchenne muscular dystrophy shows a BMP4-Induced Molecular Signature. bioRxiv, 2024.04.19.590266.","DOI":"10.1101\/2024.04.19.590266"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrg3742","article-title":"Engineering adeno-associated viruses for clinical gene therapy","volume":"15","author":"Kotterman","year":"2014","journal-title":"Nat. Rev. Genet."},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Labb\u00e9, R.P., Vessillier, S., and Rafiq, Q.A. (2021). Lentiviral Vectors for T Cell Engineering: Clinical Applications, Bioprocessing and Future Perspectives. Viruses, 13.","DOI":"10.3390\/v13081528"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12943-022-01550-8","article-title":"Genome editing via non-viral delivery platforms: Current progress in personalized cancer therapy","volume":"21","author":"Lan","year":"2022","journal-title":"Mol. Cancer"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1517\/17425247.2016.1121990","article-title":"Clinical potential of electroporation for gene therapy and DNA vaccine delivery","volume":"13","author":"Lambricht","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Li, F., Wing, K., Wang, J.-H., Luu, C.D., Bender, J.A., Chen, J., Wang, Q., Lu, Q., Nguyen Tran, M.T., and Young, K.M. (2020). Comparison of CRISPR\/Cas Endonucleases for in vivo Retinal Gene Editing. Front. Cell. Neurosci., 14.","DOI":"10.3389\/fncel.2020.570917"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1146\/annurev-chembioeng-080615-034711","article-title":"Engineering Delivery Vehicles for Genome Editing","volume":"7","author":"Nelson","year":"2016","journal-title":"Annu. Rev. Chem. Biomol. Eng."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.gpb.2022.12.003","article-title":"Superior Fidelity and Distinct Editing Outcomes of SaCas9 Compared with SpCas9 in Genome Editing","volume":"21","author":"Yang","year":"2023","journal-title":"Genom. Proteom. Bioinform."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41422-019-0165-4","article-title":"CasX: A new and small CRISPR gene-editing protein","volume":"29","author":"Yang","year":"2019","journal-title":"Cell Res."},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"Nakagawa, R., Ishiguro, S., Okazaki, S., Mori, H., Tanaka, M., Aburatani, H., Yachie, N., Nishimasu, H., and Nureki, O. (2022). Engineered Campylobacter jejuni Cas9 variant with enhanced activity and broader targeting range. Commun. Biol., 5.","DOI":"10.1038\/s42003-022-03149-7"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1080\/15476286.2018.1504546","article-title":"PAM identification by CRISPR-Cas effector complexes: Diversified mechanisms and structures","volume":"16","author":"Gleditzsch","year":"2019","journal-title":"RNA Biol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"101188","DOI":"10.1016\/j.omtm.2024.101188","article-title":"Recombinant AAV genome size effect on viral vector production, purification, and thermostability","volume":"32","author":"Ibreljic","year":"2024","journal-title":"Mol. Ther.-Methods Clin. Dev."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/emmm.201302948","article-title":"Effective delivery of large genes to the retina by dual AAV vectors","volume":"6","author":"Trapani","year":"2014","journal-title":"EMBO Mol. Med."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"6450","DOI":"10.1093\/nar\/gkv601","article-title":"Development of an intein-mediated split\u2013Cas9 system for gene therapy","volume":"43","author":"Truong","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00109-020-02034-2","article-title":"Evolving AAV-delivered therapeutics towards ultimate cures","volume":"99","author":"He","year":"2021","journal-title":"J. Mol. Med."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.nmd.2023.09.008","article-title":"261st ENMC International Workshop: Management of safety issues arising following AAV gene therapy. 17th-19th June 2022, Hoofddorp, The Netherlands","volume":"33","author":"Servais","year":"2023","journal-title":"Neuromuscul. Disord."},{"key":"ref_179","doi-asserted-by":"crossref","unstructured":"Manini, A., Abati, E., Nuredini, A., Corti, S., and Comi, G.P. (2021). Adeno-Associated Virus (AAV)-Mediated Gene Therapy for Duchenne Muscular Dystrophy: The Issue of Transgene Persistence. Front. Neurol., 12.","DOI":"10.3389\/fneur.2021.814174"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.molcel.2022.02.002","article-title":"Chimeric CRISPR-CasX enzymes and guide RNAs for improved genome editing activity","volume":"82","author":"Tsuchida","year":"2022","journal-title":"Mol. Cell"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1016\/j.cell.2021.08.028","article-title":"Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species","volume":"184","author":"Tabebordbar","year":"2021","journal-title":"Cell"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.7150\/thno.89380","article-title":"Understanding AAV vector immunogenicity: From particle to patient","volume":"14","author":"Dhungel","year":"2024","journal-title":"Theranostics"},{"key":"ref_183","doi-asserted-by":"crossref","unstructured":"Ertl, H.C.J. (2022). Immunogenicity and toxicity of AAV gene therapy. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.975803"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41551-023-01129-8","article-title":"Rational immunosilencing of a promiscuous T-cell epitope in the capsid of an adeno-associated virus","volume":"8","author":"Bing","year":"2024","journal-title":"Nat. Biomed. Eng."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.omtm.2023.08.015","article-title":"Modifying immune responses to adeno-associated virus vectors by capsid engineering","volume":"30","author":"Bentler","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.copbio.2019.01.002","article-title":"Engineering the AAV capsid to evade immune responses","volume":"60","author":"Barnes","year":"2019","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1016\/j.ymthe.2022.05.023","article-title":"Serum extracellular vesicles for delivery of CRISPR-CAS9 ribonucleoproteins to modify the dystrophin gene","volume":"30","author":"Majeau","year":"2022","journal-title":"Mol. Ther."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"7101","DOI":"10.1038\/s41467-021-26714-w","article-title":"Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice","volume":"12","author":"Kenjo","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.actbio.2025.03.032","article-title":"Effective delivery of CRISPR\/dCas9-SAM for multiplex gene activation based on mesoporous silica nanoparticles for bladder cancer therapy","volume":"197","author":"Xu","year":"2025","journal-title":"Acta Biomater."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/s41467-020-14957-y","article-title":"Extracellular nanovesicles for packaging of CRISPR-Cas9 protein and sgRNA to induce therapeutic exon skipping","volume":"11","author":"Gee","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1038\/s41467-020-17029-3","article-title":"Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing","volume":"11","author":"Wei","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_192","doi-asserted-by":"crossref","unstructured":"Wang, J., Ding, Y., Chong, K., Cui, M., Cao, Z., Tang, C., Tian, Z., Hu, Y., Zhao, Y., and Jiang, S. (2024). Recent Advances in Lipid Nanoparticles and Their Safety Concerns for mRNA Delivery. Vaccines, 12.","DOI":"10.3390\/vaccines12101148"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"7509","DOI":"10.7150\/thno.77259","article-title":"Lipid nanoparticles for delivery of RNA therapeutics: Current status and the role of in vivo imaging","volume":"12","author":"Jung","year":"2022","journal-title":"Theranostics"},{"key":"ref_194","doi-asserted-by":"crossref","unstructured":"Kularatne, R.N., Crist, R.M., and Stern, S.T. (2022). The Future of Tissue-Targeted Lipid Nanoparticle-Mediated Nucleic Acid Delivery. Pharmaceuticals, 15.","DOI":"10.3390\/ph15070897"},{"key":"ref_195","doi-asserted-by":"crossref","unstructured":"Shoji, E., Sakurai, H., Nishino, T., Nakahata, T., Heike, T., Awaya, T., Fujii, N., Manabe, Y., Matsuo, M., and Sehara-Fujisawa, A. (2015). Early pathogenesis of Duchenne muscular dystrophy modelled in patient-derived human induced pluripotent stem cells. Sci. Rep., 5.","DOI":"10.1038\/srep12831"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13395-020-00224-7","article-title":"Acute conversion of patient-derived Duchenne muscular dystrophy iPSC into myotubes reveals constitutive and inducible over-activation of TGF\u03b2-dependent pro-fibrotic signaling","volume":"10","author":"Caputo","year":"2020","journal-title":"Skelet. Muscle"},{"key":"ref_197","doi-asserted-by":"crossref","unstructured":"Palmieri, L., Pili, L., Jaber, A., Hong, A.V., Moula, M., El-Khoury, R., Brochiet, G., Bigot, A., Israeli, D., and Richard, I. (2024). Disease exacerbation in MYOrganoids derived from Duchenne Muscular Dystrophy iPSC reveals limitations of microdystrophin therapeutic efficacy. bioRxiv, 2023.07.26.550063.","DOI":"10.1101\/2023.07.26.550063"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1111\/febs.12267","article-title":"The mdx mouse model as a surrogate for Duchenne muscular dystrophy","volume":"280","author":"Partridge","year":"2013","journal-title":"FEBS J."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"dmm037655","DOI":"10.1242\/dmm.037655","article-title":"CRISPR\/Cas9-generated mouse model of Duchenne muscular dystrophy recapitulating a newly identified large 430 kb deletion in the human DMD gene","volume":"12","author":"Egorova","year":"2019","journal-title":"Dis. Models Mech."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3233\/JND-170218","article-title":"Creation of a Novel Humanized Dystrophic Mouse Model of Duchenne Muscular Dystrophy and Application of a CRISPR\/Cas9 Gene Editing Therapy","volume":"4","author":"Young","year":"2017","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1096\/fj.12-224170","article-title":"Low dystrophin levels increase survival and improve muscle pathology and function in dystrophin\/utrophin double-knockout mice","volume":"27","author":"Hulsker","year":"2013","journal-title":"FASEB J."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s40478-022-01355-2","article-title":"Duchenne muscular dystrophy trajectory in R-DMDdel52 preclinical rat model identifies COMP as biomarker of fibrosis","volume":"10","author":"Taglietti","year":"2022","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_203","doi-asserted-by":"crossref","unstructured":"Larcher, T., Lafoux, A., Tesson, L., Remy, S., Thepenier, V., Fran\u00e7ois, V., Le Guiner, C., Goubin, H., Dutilleul, M., and Guigand, L. (2014). Characterization of dystrophin deficient rats: A new model for Duchenne muscular dystrophy. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0110371"},{"key":"ref_204","doi-asserted-by":"crossref","unstructured":"Nakamura, K., Fujii, W., Tsuboi, M., Tanihata, J., Teramoto, N., Takeuchi, S., Naito, K., Yamanouchi, K., and Nishihara, M. (2014). Generation of muscular dystrophy model rats with a CRISPR\/Cas system. Sci. Rep., 4.","DOI":"10.1038\/srep05635"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"dmm047704","DOI":"10.1242\/dmm.047704","article-title":"Cardiovascular phenotype of the Dmd(mdx) rat\u2014a suitable animal model for Duchenne muscular dystrophy","volume":"14","author":"Ebner","year":"2021","journal-title":"Dis. Model. Mech."},{"key":"ref_206","doi-asserted-by":"crossref","unstructured":"Otake, M., Imamura, M., Enya, S., Kangawa, A., Shibata, M., Ozaki, K., Kimura, K., Ono, E., and Aoki, Y. (2024). Severe cardiac and skeletal manifestations in DMD-edited microminipigs: An advanced surrogate for Duchenne muscular dystrophy. Commun. Biol., 7.","DOI":"10.1038\/s42003-024-06222-5"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.molmed.2024.04.013","article-title":"Pig models for translational Duchenne muscular dystrophy research","volume":"30","author":"Stirm","year":"2024","journal-title":"Trends Mol. Med."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00335-011-9382-y","article-title":"Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies","volume":"23","author":"Kornegay","year":"2012","journal-title":"Mamm. Genome"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13395-020-00239-0","article-title":"X-linked muscular dystrophy in a Labrador Retriever strain: Phenotypic and molecular characterisation","volume":"10","author":"Calmels","year":"2020","journal-title":"Skelet. Muscle"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41591-018-0326-x","article-title":"Identification of preexisting adaptive immunity to Cas9 proteins in humans","volume":"25","author":"Charlesworth","year":"2019","journal-title":"Nat. Med."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1038\/s41467-018-05843-9","article-title":"Cas9 immunity creates challenges for CRISPR gene editing therapies","volume":"9","author":"Crudele","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/bs.pmbts.2020.12.003","article-title":"Chapter Eight\u2014Immune responses to CRISPR-Cas protein","volume":"Volume 178","author":"Ghosh","year":"2021","journal-title":"Progress in Molecular Biology and Translational Science"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1038\/s41467-023-36452-w","article-title":"A versatile, high-efficiency platform for CRISPR-based gene activation","volume":"14","author":"Heidersbach","year":"2023","journal-title":"Nat. Commun."}],"container-title":["Muscles"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2813-0413\/4\/4\/52\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T14:31:06Z","timestamp":1762785066000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2813-0413\/4\/4\/52"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":213,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["muscles4040052"],"URL":"https:\/\/doi.org\/10.3390\/muscles4040052","relation":{},"ISSN":["2813-0413"],"issn-type":[{"value":"2813-0413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]}}}